To evaluate robustness of findings, we estimated models that included statins (negative control not expected to influence drug-related poisoning risk) and benzodiazepines (which are common and known to interact with buprenorphine in contributing to increased drug-related poisonings16) as time-varying covariates. We conducted sensitivity analyses limiting analyses to individuals who had an insurance claim for an OUD diagnosis in the 6 months preceding or including treatment initiation, as well as analyses excluding individuals with cooccurring alcohol use disorder to elucidate associations of naltrexone specifically, given its dual indications for alcohol use disorder and OUD.
